Overview

Atenolol for the Prevention of Osteoporosis (APO)

Status:
Recruiting
Trial end date:
2025-01-20
Target enrollment:
Participant gender:
Summary
Evaluate whether treatment with a widely used beta blocker, atenolol, will prevent bone loss at the lower back and hip in postmenopausal women.
Phase:
Phase 3
Details
Lead Sponsor:
Sundeep Khosla, M.D.
Collaborators:
Columbia University
MaineHealth
University of California, San Francisco
Treatments:
Atenolol